What is AnTolRx?
AnTolRx is a biopharmaceutical company dedicated to revolutionizing the treatment of autoimmune diseases. The company leverages a proprietary platform designed to selectively target pathogenic immune cells, aiming to induce an anti-inflammatory phenotype. Their innovative approach includes the utilization of tolerogenic nanoparticles to combat central nervous system inflammation, addressing critical unmet needs in the autoimmunity field. AnTolRx's client base comprises individuals seeking advanced therapeutic options for autoimmune conditions.
How much funding has AnTolRx raised?
AnTolRx has raised a total of $5M across 2 funding rounds:
Private Equity
$1M
Series A
$4M
Private Equity (2016): $1M, investors not publicly disclosed
Series A (2016): $4M led by Pfizer Inc and JDRF
Key Investors in AnTolRx
Pfizer Inc
Pfizer Inc. is a global biopharmaceutical giant focused on researching, developing, and marketing medicines and vaccines across various therapeutic areas, including inflammation and immunology, indicating a strategic interest in AnTolRx's autoimmune disease focus.
JDRF
JDRF is a non-profit organization dedicated to funding research for Type 1 Diabetes, suggesting a commitment to advancing treatments for autoimmune conditions, aligning with AnTolRx's broader mission.
What's next for AnTolRx?
The recent major strategic investment signifies a pivotal moment for AnTolRx, likely enabling the company to accelerate its research and development pipeline, potentially moving its patented therapies closer to clinical trials and market entry. This enterprise-level funding suggests strong investor confidence in AnTolRx's unique approach to autoimmune disease treatment and its potential for significant market impact. The company is poised to further its mission of addressing complex immunological disorders through advanced therapeutic strategies.
See full AnTolRx company page
